Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.7% – Should You Sell?

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s share price dropped 0.7% during trading on Monday . The company traded as low as $1.35 and last traded at $1.40. Approximately 114,646 shares traded hands during trading, a decline of 53% from the average daily volume of 245,140 shares. The stock had previously closed at $1.41.

Analyst Upgrades and Downgrades

TLSA has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Tiziana Life Sciences Trading Down 13.3%

The business has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.46.

Tiziana Life Sciences (NASDAQ:TLSA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($0.28) EPS for the quarter.

Institutional Trading of Tiziana Life Sciences

Large investors have recently made changes to their positions in the company. Marshall Wace LLP raised its stake in Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after buying an additional 14,005 shares during the period. Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences during the third quarter valued at approximately $520,000. Jane Street Group LLC increased its holdings in shares of Tiziana Life Sciences by 968.2% during the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after acquiring an additional 151,858 shares in the last quarter. Zhang Financial LLC raised its position in shares of Tiziana Life Sciences by 12.0% during the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after purchasing an additional 12,000 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Tiziana Life Sciences by 413.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after purchasing an additional 88,830 shares in the last quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.